triheptanoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5399 | 620-67-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Triheptanoin is a medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provide a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 30, 2020 | FDA | ULTRAGENYX PHARM INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX17 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Disorder of fatty acid metabolism | indication | 39929009 | |
| Long-chain fatty acid transport deficiency | indication | 426387005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 100% w/w | DOJOLVI | ULTRAGENYX PHARM INC | N213687 | June 30, 2020 | RX | LIQUID | ORAL | June 30, 2025 | NEW CHEMICAL ENTITY |
| 100% w/w | DOJOLVI | ULTRAGENYX PHARM INC | N213687 | June 30, 2020 | RX | LIQUID | ORAL | June 30, 2027 | INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD) |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D11465 | KEGG_DRUG |
| 2P6O7CFW5K | UNII |
| C2604598 | UMLSCUI |
| CHEMBL4297585 | ChEMBL_ID |
| 69286 | PUBCHEM_CID |
| DB11677 | DRUGBANK_ID |
| 11431 | IUPHAR_LIGAND_ID |
| 1313234 | RXNORM |
| 336029 | MMSL |
| 38592 | MMSL |
| d09588 | MMSL |
| 926370002 | SNOMEDCT_US |
| 926378009 | SNOMEDCT_US |
| 4039553 | VANDF |
| 018432 | NDDF |
| C531010 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10893 | INN_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| DOJOLVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69794-050 | LIQUID | 0.96 g | ORAL | NDA | 25 sections |